Row breaks out over German funding of short acting diabetes treatment

doi:10.1136/bmj.332.7546.874-c

BMJ 2006;332:874 (15 April), doi:10.1136/bmj.332.7546.874-c

News extra

Row breaks out over German funding of short acting diabetes treatment

Heidelberg Annette Tuffs

The German independent Institute for Quality and Economic Efficiency in Health Care has come under fire from doctors, patients, politicians, and the drugs industry for questioning the use of short acting insulin analogues for late onset (type 2) diabetes. The institute is Germany’s equivalent of the National Institute for Health and Clinical Excellence (NICE) in England.

Following the institute’s report, a federal committee has announced that it intends to forbid health insurance companies from paying for costly short acting insulin analogues rather than insulin.

No other institution in Europe has published recommendations on the use of these drugs, but NICE published recommendations on long acting insulin in December 2002 (www.nice.org.uk/page.aspx?o=43424).

The institute was commissioned by the German Federal Joint Committee of doctors, health insurance companies, and patients, to study three different types of short acting insulin analogues available in Germany. The institute was founded in August 2004 . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?